Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799

被引：0
|
作者：
Reck, M. [1 ]
Lee, K. H. [2 ]
Frost, N. [3 ,4 ,5 ,6 ]
Kowalski, D. M. [7 ]
Breder, V. [8 ]
Pollock, T. [9 ]
Reguart, N. [10 ]
Houghton, B. [11 ]
Quantin, X. [12 ]
Keller, S. M. [13 ]
Liu, H. [13 ]
Piperdi, B. [13 ]
Jabbour, S. K. [14 ]
机构：
[1] German Ctr Lung Res, Airway Res Ctr North, Lungenclin, Grosshansdorf, Germany
[2] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[3] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany
[4] Free Univ Berlin, Berlin, Germany
[5] Humboldt Univ, Berlin, Germany
[6] Berlin Inst Hlth, Berlin, Germany
[7] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[8] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[9] Southwestern Reg Med Ctr Inc, Canc Treatment Ctr Amer, Tulsa, OK USA
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Port Macquarie Base Hosp, Mid North Coast Canc Inst, Port Macquarie, NSW, Australia
[12] Montpellier Canc Inst, Dept Med Oncol, Montpellier, France
[13] Merck & Co Inc, Kenilworth, NJ USA
[14] Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
nonesmall-cell lung cancer; Pembrolizumab; chemoradiation therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA02.03
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [31] Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial
    Smeenk, M. M.
    van Diessen, J. N. A.
    Boellaard, T. N.
    Hartemink, K. J.
    de Vries, J. F.
    Badrising, S. K.
    Wondergem, M.
    Wittenberg, R.
    Monkhorst, K.
    van den Heuvel, M. M.
    Theelen, W. S. M. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S157 - S157
  • [32] Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage III nsclc in china
    Jiang, Xiaotong
    Chen, Jinyu
    Zheng, Min
    Jia, Hanxue
    PLOS ONE, 2022, 17 (06):
  • [33] Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NCSLC)
    Jokhadze, N.
    Kiladze, I.
    Katselashvili, L.
    Kacharava, M.
    Jankarashvili, N.
    Zumbadze, I.
    Kalandarishvili, N.
    Melkadze, T.
    Gogua, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S66 - S67
  • [34] Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
    Paz-Ares, L.
    Langer, C. J.
    Novello, S.
    Halmos, B.
    Cheng, Y.
    Gadgeel, S. M.
    Hui, R.
    Sugawara, S.
    Borghaei, H.
    Cristescu, R.
    Aurora-Garg, D.
    Albright, A.
    Loboda, A.
    Kobie, J.
    Lunceford, J.
    Ayers, M.
    Lubiniecki, G. M.
    Pietanza, M. C.
    Piperdi, B.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 917 - +
  • [35] VIBOSTOLIMAB PLUS PEMBROLIZUMAB WITH/WITHOUT DOCETAXEL VS DOCETAXEL IN NSCLC AFTER PLATINUM CHEMOTHERAPY AND IMMUNOTHERAPY
    Peters, Solange
    Lee, Dae Ho
    Ramlau, Rodryg
    Halmos, Balazs
    Schumann, Christian
    Planchard, David
    Bhagwati, Niyati
    Chen, Diana
    Kush, Debra
    Novello, Silvia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A492 - A492
  • [36] KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
    Cheng, Y.
    Zhang, L.
    Hu, J.
    Wang, D.
    Hu, C.
    Zhou, J.
    Wu, L.
    Cao, L.
    Liu, J.
    Zhang, H.
    Sun, H.
    Wang, Z.
    Gao, H.
    Sun, Y.
    Li, B.
    Schwarzenberger, P.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1018 - S1019
  • [37] Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy
    Peters, S.
    Lee, D. H.
    Ramlau, R.
    Halmos, B.
    Schumann, C.
    Planchard, D.
    Bhagwati, N.
    Chen, Q.
    Kush, D.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1012
  • [38] Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%
    Brahmer, J.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Riccio, A.
    Yang, J.
    Pietanza, M. C.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1793 - S1794
  • [39] Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)
    Tachihara, M.
    Tsujino, K.
    Shimokawa, M.
    Ishihara, T.
    Hayashi, H.
    Sato, Y.
    Kurata, T.
    Sugawara, S.
    Shiraishi, Y.
    Teraoka, S.
    Azuma, K.
    Daga, H.
    Yamaguchi, M.
    Kodaira, T.
    Satouchi, M.
    Yamamoto, N.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S64 - S64
  • [40] KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
    Tabernero, Josep
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Janjigian, Yelena Yuriy
    Bhagia, Pooja
    Li, Kan
    Adelberg, David
    Qin, Shu Kui
    FUTURE ONCOLOGY, 2021, 17 (22) : 2847 - 2855
12345